Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Protocol EC-FV-05: An Open-label, Multi-center, Extension Study of EC145 Administered Weeks 1 and 3 of a 4-Week Cycle in Subjects Enrolled in a Previous Study With EC145

Next Previous
Trial Profile

Protocol EC-FV-05: An Open-label, Multi-center, Extension Study of EC145 Administered Weeks 1 and 3 of a 4-Week Cycle in Subjects Enrolled in a Previous Study With EC145

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vintafolide (Primary)
  • Indications Endometrial cancer; Non-small cell lung cancer; Ovarian cancer
  • Focus Adverse reactions
  • Sponsors Endocyte; Merck Sharp & Dohme

Most Recent Events

  • 23 Aug 2017 Status changed from active, no longer recruiting to completed.
  • 19 Jan 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
  • 05 Jun 2014 Planned End Date changed from 1 Dec 2016 to 1 Apr 2018 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top